<DOC>
	<DOCNO>NCT02877628</DOCNO>
	<brief_summary>Prospective , non-randomized , open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric study . Donor recipient CYP3A5 genotype recipient ABCB1 communicate clinician patient study .</brief_summary>
	<brief_title>Immunosuppressive Therapy Optimization : Development Population Pharmacokinetic-pharmacodynamic ( PK-PD ) Model Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Adults 18 Liver transplant recipient Treated immunosuppressive protocol tacrolimus Informed study refuse participate Patients participate study procedure incompatible present study . Patients legal protection/deprived liberty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>liver transplantation</keyword>
</DOC>